Request for Nominations for Voting Members on a Public Advisory Committee; Technical Electronic Product Radiation Safety Standards Committee, 2009-2010 [2025-00310]
Download as PDF
khammond on DSK9W7S144PROD with NOTICES
Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices
Advisory Committee (the Committee).
The Committee is a discretionary
Federal advisory committee established
to provide advice to the Commissioner.
The Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to helping to ensure safe and
effective drugs for human use and, as
required, any other product for which
FDA has regulatory responsibility.
The Committee reviews and evaluates
available data concerning the safety and
effectiveness of marketed and
investigational human drug products for
use in the treatment of infectious
diseases and disorders and makes
appropriate recommendations to the
Commissioner of Food and Drugs.
Pursuant to its charter, the Committee
shall consist of a core of 13 voting
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
authorities knowledgeable in the fields
of infectious disease, internal medicine,
microbiology, pediatrics, epidemiology
or statistics, and related specialties.
Members will be invited to serve for
overlapping terms of up to 4 years. NonFederal members of this committee will
serve as Special Government Employees
or representatives. Federal members
will serve as Regular Government
Employees or Ex-Officios. The core of
voting members may include one
technically qualified member, selected
by the Commissioner or designee, who
is identified with consumer interests
and is recommended by either a
consortium of consumer-oriented
organizations or other interested
persons. In addition to the voting
members, the Committee may include
one non-voting representative member
who is identified with industry
interests. There may also be an alternate
industry representative.
The Commissioner or designee shall
have the authority to select members of
other scientific and technical FDA
advisory committees (normally not to
exceed 10 members) to serve
temporarily as voting members and to
designate consultants to serve
temporarily as voting members when:
(1) expertise is required that is not
available among current voting standing
members of the Committee (when
additional voting members are added to
the Committee to provide needed
expertise, a quorum will be based on the
combined total of regular and added
members) or (2) to comprise a quorum
when, because of unforeseen
circumstances, a quorum is or will be
lacking. Because of the size of the
Committee and the variety in the types
of issues that it will consider, FDA may,
VerDate Sep<11>2014
17:28 Jan 08, 2025
Jkt 265001
in connection with a particular
committee meeting, specify a quorum
that is less than a majority of the current
voting members. The Agency’s
regulations (21 CFR 14.22(d)) authorize
a committee charter to specify quorum
requirements.
If functioning as a medical device
panel, an additional non-voting
representative member of consumer
interests and an additional non-voting
representative member of industry
interests will be included in addition to
the voting members.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/advisory-committees/
antimicrobial-drugs-advisorycommittee-formerly-known-antiinfective-drugs-advisory-committee/
antimicrobial-drugs-advisorycommittee-formerly-known-antiinfective-drugs-advisory-committee or
by contacting the Designated Federal
Officer (see FOR FURTHER INFORMATION
CONTACT). In light of the fact that no
change has been made to the committee
name or description of duties, no
amendment will be made to 21 CFR
14.100.
This notice is issued under the
Federal Advisory Committee Act as
amended (5 U.S.C. 1001 et seq.). For
general information related to FDA
advisory committees, please visit us at
https://www.fda.gov/
AdvisoryCommittees/default.htm.
Dated: December 31, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025–00357 Filed 1–8–25; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2018–N–3233]
Request for Nominations for Voting
Members on a Public Advisory
Committee; Technical Electronic
Product Radiation Safety Standards
Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting
nominations for voting members to
serve on the Technical Electronic
Product Radiation Safety Standards
Committee (TEPRSSC) in the Center for
Devices and Radiological Health.
SUMMARY:
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
2009
Nominations will be accepted for
current and upcoming vacancies
effective January 1, 2025, with this
notice. FDA seeks to include the views
of women and men, members of all
racial and ethnic groups, and
individuals with and without
disabilities on its advisory committees
and, therefore, encourages nominations
of appropriately qualified candidates
from these groups.
DATES: Nominations received on or
before March 11, 2025, will be given
first consideration for membership on
TEPRSSC. Nominations received after
March 11, 2025, will be considered for
nomination to the committee as later
vacancies occur.
ADDRESSES: All nominations for
membership should be sent
electronically by accessing FDA’s
Advisory Committee Membership
Nomination Portal at https://
www.accessdata.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm or by
mail to Advisory Committee Oversight
and Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5103, Silver Spring,
MD 20993–0002. Information about
becoming a member on an FDA advisory
committee can also be obtained by
visiting FDA’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
FOR FURTHER INFORMATION CONTACT:
Akinola Awojope, Office of
Management Services, Center for
Devices and Radiological Health, Food
and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5216,
Silver Spring, MD 20993–0002, 301–
636–0512, email: Akinola.Awojope@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for voting
members on TEPRSSC that include five
general public representatives and five
government representatives.
I. General Description of the
Committee’s Duties
The committee provides advice and
consultation to the Commissioner of
Food and Drugs (the Commissioner) on
the technical feasibility, reasonableness,
and practicability of performance
standards for electronic products to
control the emission of radiation from
such products, and may recommend
electronic product radiation safety
standards to the Commissioner for
consideration.
II. Criteria for Voting Members
The committee consists of a core of 15
voting members including the Chair.
Members and the Chair are selected by
E:\FR\FM\10JAN1.SGM
10JAN1
2010
Federal Register / Vol. 90, No. 6 / Friday, January 10, 2025 / Notices
the Commissioner or designee from
among authorities knowledgeable in the
fields of science or engineering,
applicable to electronic product
radiation safety. Members will be
invited to serve for overlapping terms of
up to 4 years. Terms of more than 2
years are contingent upon the renewal
of the committee by appropriate action
prior to its expiration.
III. Nomination Procedures
Any interested person may nominate
one or more qualified individuals for
membership on the committee. Selfnominations are also accepted.
Nominations must include a current,
complete résumé or curriculum vitae for
each nominee, including current
business address and/or home address,
telephone number, and email address if
available and a signed copy of the
Acknowledgement and Consent form
available at the FDA Advisory
Nomination Portal (see ADDRESSES).
Nominations must also specify the
advisory committee for which the
nominee is recommended. Nominations
must also acknowledge that the
nominee is aware of the nomination
unless self-nominated. FDA will ask
potential candidates to provide detailed
information concerning such matters
related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. 1001 et seq.), and 21 CFR part 14,
relating to advisory committees.
Dated: December 27, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025–00310 Filed 1–8–25; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Meeting of the Advisory Commission
on Childhood Vaccines
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
khammond on DSK9W7S144PROD with NOTICES
AGENCY:
In accordance with the
Federal Advisory Committee Act, this
notice announces that the Advisory
Commission on Childhood Vaccines
(ACCV) has scheduled a public meeting.
Information about ACCV and the agenda
for this meeting can be found on the
SUMMARY:
VerDate Sep<11>2014
17:28 Jan 08, 2025
Jkt 265001
ACCV website at https://www.hrsa.gov/
advisory-committees/vaccines/
index.html.
DATES: The ACCV meeting will be held
on January 29, 2025, 12 p.m. eastern
time (ET)–4 p.m. ET and January 30,
2025, 12 p.m. ET–4 p.m. ET.
ADDRESSES: The meeting will be held by
Zoom webinar. For meeting information
updates and instructions for joining
remote meetings, go to the ACCV
website meeting page at https://
www.hrsa.gov/advisory-committees/
vaccines/meetings.html.
FOR FURTHER INFORMATION CONTACT: Pita
Gomez, Principal Staff Liaison, Division
of Injury Compensation Programs,
HRSA, 5600 Fishers Lane, 8W–25A,
Rockville, Maryland 20857; 800–338–
2382; or ACCV@hrsa.gov.
SUPPLEMENTARY INFORMATION: ACCV
provides advice and recommendations
to the Secretary of Health and Human
Services on policy, program
development, and other matters of
significance related to implementation
of the National Vaccine Injury
Compensation Program and concerning
other matters as described under section
2119 of the Public Health Service Act
(42 U.S.C. 300aa–19).
Since priorities dictate meeting times,
be advised that start times, end times,
and agenda items are subject to change.
Refer to the ACCV website listed above
for any meeting updates that may occur.
For the January 2025 meeting, agenda
items may include, but are not limited
to: updates from the Division of Injury
Compensation Programs, Department of
Justice, Office of Infectious Disease and
HIV/AIDS Policy (Department of Health
and Human Services), Immunization
Safety Office (Centers for Disease
Control and Prevention), National
Institute of Allergy and Infectious
Diseases (National Institutes of Health),
and Center for Biologics Evaluation and
Research (Food and Drug
Administration). Refer to the ACCV
website listed above for all current and
updated information concerning the
January 2025 ACCV meeting, including
the draft agenda that will be posted 15
calendar days before the meeting.
This meeting is open to the public
and requires registration. Registration
details will be provided on our ACCV
website at https://www.hrsa.gov/
advisory-committees/vaccines/
meetings.html. All registrants will be
asked to provide their name, affiliation,
and email address. After registration,
individuals will receive personalized
Zoom information via email.
Members of the public will have the
opportunity to provide comments.
Public participants may submit written
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
statements in advance of the meeting.
Oral comments will be honored in the
order they are requested and may be
limited as time allows. Requests to
submit a written statement or make oral
comments to ACCV should be sent to
Pita Gomez using the contact
information above at least 5 business
days before the meeting date.
Individuals who need special
assistance or another reasonable
accommodation should notify Pita
Gomez using the contact information
listed above at least 10 business days
before the meeting.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2025–00389 Filed 1–8–25; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of Minority Health,
Organizational Structure
Office of Minority Health,
Office of the Secretary, Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
This notice provides an
update to the organizational structure
for the Department of Health and
Human Services (HHS), Office of the
Secretary (OS), Office of Minority
Health (OMH). OMH has changed the
name of the Division of Information and
Education (DIE acronym), as noted in an
April 11, 1995 Federal Register Notice,
to the Division of Strategic
Communication and Community
Engagement (DCE acronym). This name
change better aligns with the functions
of the division and provides for a more
socially acceptable acronym. The
functions of the division are unchanged
from the April 11, 1995 Federal Register
Notice.
SUPPLEMENTARY INFORMATION: OMH
develops policies and programs for the
improvement of the health status of
racial and ethnic minority populations
and coordinates minority health
activities across HHS. The
establishment of OMH is noted in 50 FR
50847–48 (December 12, 1985). OMH’s
organization, functions, and delegations
of authority are noted in 60 FR 18418–
19 (April 11, 1995), as amended in 78
FR 59699–700 (September 27, 2013).
This notice provides an update to Part
A, Office of the Secretary, Statement of
Organization, Functions, and
Delegations of Authority for the U.S.
Department of Health and Human
Services at Chapter AC, to change the
name of the OMH Division of
SUMMARY:
E:\FR\FM\10JAN1.SGM
10JAN1
Agencies
[Federal Register Volume 90, Number 6 (Friday, January 10, 2025)]
[Notices]
[Pages 2009-2010]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2025-00310]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-3233]
Request for Nominations for Voting Members on a Public Advisory
Committee; Technical Electronic Product Radiation Safety Standards
Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for voting members to serve on the Technical Electronic
Product Radiation Safety Standards Committee (TEPRSSC) in the Center
for Devices and Radiological Health. Nominations will be accepted for
current and upcoming vacancies effective January 1, 2025, with this
notice. FDA seeks to include the views of women and men, members of all
racial and ethnic groups, and individuals with and without disabilities
on its advisory committees and, therefore, encourages nominations of
appropriately qualified candidates from these groups.
DATES: Nominations received on or before March 11, 2025, will be given
first consideration for membership on TEPRSSC. Nominations received
after March 11, 2025, will be considered for nomination to the
committee as later vacancies occur.
ADDRESSES: All nominations for membership should be sent electronically
by accessing FDA's Advisory Committee Membership Nomination Portal at
https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or
by mail to Advisory Committee Oversight and Management Staff, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993-0002. Information about becoming a member on an
FDA advisory committee can also be obtained by visiting FDA's website
at https://www.fda.gov/AdvisoryCommittees/default.htm.
FOR FURTHER INFORMATION CONTACT: Akinola Awojope, Office of Management
Services, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5216, Silver
Spring, MD 20993-0002, 301-636-0512, email:
[email protected].
SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting
members on TEPRSSC that include five general public representatives and
five government representatives.
I. General Description of the Committee's Duties
The committee provides advice and consultation to the Commissioner
of Food and Drugs (the Commissioner) on the technical feasibility,
reasonableness, and practicability of performance standards for
electronic products to control the emission of radiation from such
products, and may recommend electronic product radiation safety
standards to the Commissioner for consideration.
II. Criteria for Voting Members
The committee consists of a core of 15 voting members including the
Chair. Members and the Chair are selected by
[[Page 2010]]
the Commissioner or designee from among authorities knowledgeable in
the fields of science or engineering, applicable to electronic product
radiation safety. Members will be invited to serve for overlapping
terms of up to 4 years. Terms of more than 2 years are contingent upon
the renewal of the committee by appropriate action prior to its
expiration.
III. Nomination Procedures
Any interested person may nominate one or more qualified
individuals for membership on the committee. Self-nominations are also
accepted. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business address and/or home address, telephone number, and
email address if available and a signed copy of the Acknowledgement and
Consent form available at the FDA Advisory Nomination Portal (see
ADDRESSES). Nominations must also specify the advisory committee for
which the nominee is recommended. Nominations must also acknowledge
that the nominee is aware of the nomination unless self-nominated. FDA
will ask potential candidates to provide detailed information
concerning such matters related to financial holdings, employment, and
research grants and/or contracts to permit evaluation of possible
sources of conflicts of interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. 1001 et seq.), and 21 CFR part 14, relating to advisory
committees.
Dated: December 27, 2024.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025-00310 Filed 1-8-25; 8:45 am]
BILLING CODE 4164-01-P